Media ReleasesSienna Cancer Diagnostics

View All Sienna Cancer Diagnostics News

Sienna Announces Exclusive Distribution Partner Appointed for Mainland China

• GaoYuan In-Vitro Reagents Co. appointed as exclusive distributor

• China is a fast growing consumer of in-vitro diagnostic (IVD) tests

• GaoYuan to lead regulatory and approval process with China Food and Drug Administration (CFDA)

Melbourne, Australia, 7 August 2018: Sienna Cancer Diagnostics Ltd, (ASX:SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative cancer related tests, is pleased to announce it has appointed Shaanxi GaoYuan In Vitro Diagnostic Reagents Co. (“GaoYuan”) as the Company’s exclusive distribution partner for mainland China.

The distribution agreement for mainland China is a milestone in Sienna’s geographical expansion strategy. The agreement gives GaoYuan the exclusive right to sell Sienna’s in-vitro diagnostic hTERT test to pathology labs where it will be used as an adjunct to urine cytology, assisting pathologists and urologists in the diagnosis of bladder cancer.

For further information please download PDF attached:
Download this document